BioXcel Therapeutics (BTAI) Competitors $0.64 -0.02 (-3.02%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BTAI vs. GNTA, ALVR, IMAB, ACAB, ORMP, ONCY, VIRI, IFRX, PWUP, and IOBTShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Genenta Science (GNTA), AlloVir (ALVR), I-Mab (IMAB), Atlantic Coastal Acquisition Corp. II (ACAB), Oramed Pharmaceuticals (ORMP), Oncolytics Biotech (ONCY), Virios Therapeutics (VIRI), InflaRx (IFRX), PowerUp Acquisition (PWUP), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Genenta Science AlloVir I-Mab Atlantic Coastal Acquisition Corp. II Oramed Pharmaceuticals Oncolytics Biotech Virios Therapeutics InflaRx PowerUp Acquisition IO Biotech BioXcel Therapeutics (NASDAQ:BTAI) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability. Is BTAI or GNTA more profitable? Genenta Science has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -4,487.39%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-4,487.39% N/A -133.99% Genenta Science N/A N/A N/A Which has higher valuation & earnings, BTAI or GNTA? Genenta Science has lower revenue, but higher earnings than BioXcel Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.40M10.90-$179.05M-$3.56-0.18Genenta ScienceN/AN/A-$12.60MN/AN/A Do analysts prefer BTAI or GNTA? BioXcel Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 677.48%. Genenta Science has a consensus price target of $25.00, indicating a potential upside of 358.72%. Given BioXcel Therapeutics' higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer BTAI or GNTA? BioXcel Therapeutics received 236 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 67.50% of users gave BioXcel Therapeutics an outperform vote. CompanyUnderperformOutperformBioXcel TherapeuticsOutperform Votes24367.50% Underperform Votes11732.50% Genenta ScienceOutperform Votes787.50% Underperform Votes112.50% Do insiders & institutionals believe in BTAI or GNTA? 30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 28.7% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer BTAI or GNTA? In the previous week, BioXcel Therapeutics had 1 more articles in the media than Genenta Science. MarketBeat recorded 1 mentions for BioXcel Therapeutics and 0 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.46 beat BioXcel Therapeutics' score of 0.00 indicating that Genenta Science is being referred to more favorably in the news media. Company Overall Sentiment BioXcel Therapeutics Neutral Genenta Science Neutral Which has more risk & volatility, BTAI or GNTA? BioXcel Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. SummaryGenenta Science beats BioXcel Therapeutics on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.17M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.1810.05116.1015.23Price / Sales10.90400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book-0.345.594.775.07Net Income-$179.05M$153.56M$119.06M$225.46M7 Day Performance5.32%0.13%0.80%0.37%1 Month Performance19.11%15.23%5.65%3.57%1 Year Performance-83.88%41.14%36.75%29.43% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.1838 of 5 stars$0.64-3.0%$5.00+677.5%-85.4%$27.17M$2.40M-0.1890Short Interest ↑News CoverageGNTAGenenta Science2.6328 of 5 stars$5.40+3.4%$25.00+363.0%+2.1%$98.37MN/A0.007Gap UpALVRAlloVir2.5638 of 5 stars$0.85+6.2%N/A-38.1%$98.25MN/A-0.69110Upcoming EarningsShort Interest ↓News CoveragePositive NewsIMABI-Mab3.3517 of 5 stars$1.19+0.8%$8.00+572.3%-30.1%$96.90M$3.89M0.0034News CoverageACABAtlantic Coastal Acquisition Corp. IIN/A$11.55+3.5%N/A+9.0%$94.30MN/A0.004High Trading VolumeORMPOramed Pharmaceuticals1.7817 of 5 stars$2.32-2.1%N/A+35.7%$94.26M$1.34M4.5510News CoverageONCYOncolytics Biotech1.7031 of 5 stars$1.22flat$4.00+227.9%-27.2%$94.03MN/A-4.3630Positive NewsVIRIVirios Therapeutics0.1541 of 5 stars$4.87-2.4%$3.00-38.4%+747.9%$93.79MN/A-18.045Gap DownIFRXInflaRx3.5707 of 5 stars$1.57flat$13.50+759.9%-2.5%$92.44M$70,000.00-1.7660Upcoming EarningsShort Interest ↓News CoveragePWUPPowerUp AcquisitionN/A$11.69flatN/A-3.3%$90.83MN/A0.00N/ANews CoveragePositive NewsIOBTIO Biotech3.3415 of 5 stars$1.33+9.9%$9.33+601.8%+36.8%$87.62MN/A-0.9230Short Interest ↓Positive News Related Companies and Tools Related Companies Genenta Science Alternatives AlloVir Alternatives I-Mab Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Oramed Pharmaceuticals Alternatives Oncolytics Biotech Alternatives Virios Therapeutics Alternatives InflaRx Alternatives PowerUp Acquisition Alternatives IO Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BTAI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
